Characterization of a serum protein pattern from NSCLC patients treated with Gefitinib

Clinical Biochemistry

Volumn 44, Issue 10-11, 2011, Pages 936-940

  Garrisi, V M ^a   Bongarzone, I ^b   Mangia, A ^a   Cremona, M ^b   De Bortoli, M ^b   Vaghi, E ^b   Galetta, D ^a   Pastorino, U ^b   Quaranta, M ^a   Abbate, I ^a   Paradiso, A ^a  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Biomarkers; NSCLC; Proteomics; SAA; SELDI TOF

Indexed keywords

GEFITINIB; PROTEIN; SERUM AMYLOID A;

ADULT; ADVANCED CANCER; AGED; ANTIBODY RESPONSE; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR WEIGHT; PEPTIDE ANALYSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TREATMENT OUTCOME;

AGED; ALGORITHMS; BLOOD PROTEINS; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; DISEASE PROGRESSION; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; QUINAZOLINES; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 79958813499     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2011.04.013     Document Type: Article

References (10)

1. Galetta D., Rossi A., Colucci G., Gebbia V. Third-line therapy for advanced non-small lung cancer patients: a feasible therapeutic option?. Oncology 2009, 77(Suppl 1):113-121.
2. Schiller J.H., Harrington D., Belani C.P., et al. Comparison of four chemotherapy regimens for advanced Non-Small-Lung-Cancer. N Engl J Med 2002, 346:92-98.
3. Varella-Garcia M., Diebold J., Eberhard D.A., et al. EGFR fluorescence hybridisation assay: guidelines for application to non-small-lung-cancer. J Clin Pathol 2009, 62:970-977.
4. Garrisi V.M., Abbate I., Quaranta M., et al. SELDI TOF serum proteomics and breast cancer: which perspective?. Expert Rev Proteomics Dec 2008, 5(6):779-785.
5. Aresta A., Calvano C.D., Palmisano F., et al. Impact of sample preparation in peptide/protein profiling in human serum by MALDI-TOF mass spectrometry. J Pharm Biomed Anal 2008, 46(1):157-164.
6. Taguchi F., Solomon B., Gregorc V., et al. Mass spectrometry to classify non small cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst 2007, 99:838-846.
7. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst Feb 2 2000, 92(3):205-216.
8. Cremona M., Calabrò E., Randi G., et al. Elevated levels of acute-phase serum amyolid are associated with heightened of lung cancer risk. Cancer Mar 1 2010, 116(5):1326-1335.
9. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
10. Robertson G.R., Liddle C., Clarke S.J. Inflammation and altered drug clearance in cancer: transcriptional repression of a human CYP 3A4 transgene in tumor-bearing mice. Clin Pharmacol Ther 2008, 83(6):894-897.